MedRx Co., Ltd (4586.T)
JPY 84.0
(-3.45%)
JPY 84.0
(-3.45%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -933 Million JPY | 15.0% |
| 2022 | -1.09 Billion JPY | -3.54% |
| 2021 | -1.06 Billion JPY | 6.12% |
| 2020 | -1.13 Billion JPY | 30.56% |
| 2019 | -1.62 Billion JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 40.46 Million JPY | 122.98% |
| 2024 Q1 | -176.07 Million JPY | 33.03% |
| 2023 Q4 | -262.91 Million JPY | -36.91% |
| 2023 FY | -934 Million JPY | 15.0% |
| 2023 Q3 | -192.02 Million JPY | -4.56% |
| 2023 Q2 | -183.65 Million JPY | 37.74% |
| 2023 Q1 | -294.96 Million JPY | 38.14% |
| 2022 Q4 | -476.84 Million JPY | -92.49% |
| 2022 FY | -1.09 Billion JPY | -3.54% |
| 2022 Q3 | -247.72 Million JPY | 0.0% |
| 2021 FY | -1.06 Billion JPY | 6.12% |
| 2020 FY | -1.13 Billion JPY | 30.56% |
| 2019 FY | -1.62 Billion JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 5.11 Billion JPY | 118.248% |
| Takeda Pharmaceutical Company Limited | 214.07 Billion JPY | 100.436% |
| Sumitomo Pharma Co., Ltd. | -354.19 Billion JPY | 99.737% |
| Shionogi & Co., Ltd. | 171.46 Billion JPY | 100.544% |
| Wakamoto Pharmaceutical Co.,Ltd. | -195.51 Million JPY | -377.211% |
| Nippon Shinyaku Co., Ltd. | 31.38 Billion JPY | 102.973% |
| Kaken Pharmaceutical Co., Ltd. | 9.51 Billion JPY | 109.808% |
| Eisai Co., Ltd. | 53.4 Billion JPY | 101.747% |
| Morishita Jintan Co., Ltd. | 716 Million JPY | 230.307% |
| Hisamitsu Pharmaceutical Co., Inc. | 13.16 Billion JPY | 107.086% |
| Mochida Pharmaceutical Co., Ltd. | 5.8 Billion JPY | 116.078% |
| Fuso Pharmaceutical Industries,Ltd. | 1.96 Billion JPY | 147.505% |
| Nippon Chemiphar Co., Ltd. | -494 Million JPY | -88.866% |
| Tsumura & Co. | 20.01 Billion JPY | 104.661% |
| Kissei Pharmaceutical Co., Ltd. | 4.01 Billion JPY | 123.226% |
| Torii Pharmaceutical Co., Ltd. | 5.03 Billion JPY | 118.527% |
| Towa Pharmaceutical Co., Ltd. | 17.64 Billion JPY | 105.287% |
| Fuji Pharma Co., Ltd. | 3.85 Billion JPY | 124.184% |
| Zeria Pharmaceutical Co., Ltd. | 9.71 Billion JPY | 109.602% |
| KYORIN Holdings, Inc. | 6.01 Billion JPY | 115.516% |
| Taiko Pharmaceutical Co.,Ltd. | -3.07 Billion JPY | 69.698% |
| Daito Pharmaceutical Co.,Ltd. | 3.89 Billion JPY | 123.96% |
| SymBio Pharmaceuticals Limited | -811.66 Million JPY | -14.948% |
| Mizuho Medy Co.,Ltd. | 5.15 Billion JPY | 118.11% |
| Solasia Pharma K.K. | -1.13 Billion JPY | 18.086% |
| Modalis Therapeutics Corporation | -2.37 Billion JPY | 60.633% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 6.5 Billion JPY | 114.354% |
| Sawai Group Holdings Co., Ltd. | 18.88 Billion JPY | 104.94% |
| Cyfuse Biomedical K.K. | -697.43 Million JPY | -33.776% |
| Toho Holdings Co., Ltd. | 19.33 Billion JPY | 104.826% |
| Koa Shoji Holdings Co.,Ltd. | 4.38 Billion JPY | 121.29% |